Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Germinated barley, also known as Maiya in Traditional Chinese Medicine (TCM), is derived from the sprouted and dried grains of Hordeum vulgare L. In TCM, it is characterized by sweet and neutral properties and is associated with the Spleen, Stomach, and Liver meridians. Traditionally, it is used to aid digestion, harmonize the stomach, restrain lactation, and promote the flow of liver qi. Modern research indicates that total barley maiya alkaloids (TBMA), including hordenine, can inhibit prolactin secretion by modulating dopamine D2 receptors and protein kinase A targets. Furthermore, it has been shown to reduce dopamine D2 receptor expression through epigenetic mechanisms, specifically by inhibiting DNA methyltransferase-dependent DRD2 methylation. Beyond its role in prolactin regulation, germinated barley has also been investigated as a prebiotic for the nutraceutical treatment of ulcerative colitis, promoting beneficial gut bacteria.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on germinated barley.